|
December 28, 2004
|
|
|
|
|
|
|
| |
|
December 22, 2004
|
|
|
|
Smoking plays a dominant role in the development
of the disease, but genetic factors appear to establish increased
susceptibility that goes beyond the nuclear family
|
|
|
| |
|
December 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, December 17, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland & Basel, Switzerland,
November 23, 2004
|
|
|
|
deCODE will work on optimizing and bringing
into clinic trials compounds the companies have identified in their
previous genetics and drug discovery work on stroke
|
|
|
| |
|
Reykjavik, Iceland, November 2, 2004
|
|
|
|
Positive results from Phase IIa trial for
DG031, progress across pipeline underscore execution of drug development
strategy - Company has $215 million on hand
for advancing its programs
|
|
|
| |
|
Reykjavik, Iceland, October 22, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, October 19, 2004
|
|
|
|
Study achieves primary endpoints; DG031 shown
to be well-tolerated and to significantly reduce levels of leukotriene
B4 and myeloperoxidase - First ever clinical trial based upon the
isolation of a disease gene in a common disease
|
|
|
| |
|
Reykjavik, Iceland, October 8, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, October 3, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, September 23, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, September 20, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, September 10, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, August 26, 2004
|
|
|
|
No disagreements with accountants on accounting
principles or practices
|
|
|
| |
|
Reykjavik, Iceland, July 28, 2004
|
|
|
|
Advancing drug development pipeline in heart
attack, PAOD, stroke, asthma. Solid revenue streams, efficient
operations, alliance funding together add more than $7 million
to cash position in 1H04. Company now has more than $225 million
on hand for advancing its programs.
|
|
|
| |
|
Reykjavik, Iceland, July 21, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, July 2, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, June 28, 2004
|
|
|
|
Phase IIa trial of DG031, progress
towards the clinic in PAOD, stroke and asthma, solid financials
underpin development of novel drugs for major indications
|
|
|
| |
|
Reykjavik, Iceland, June 18, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, June 18, 2004
|
|
|
|
Study to conclude in late August; data will
be used in the design of an information-rich Phase III study for
the prevention of heart attack
|
|
|
| |
|
Reykjavik, Iceland, May 3, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, April 28, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, April 28, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, April 23, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, April 14, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, April 7, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, April 5, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, March 25, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, February 27, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, February 26, 2004
|
|
|
|
deCODE will conduct information-rich clinical
trials for Merck compounds, leveraging population and genetics
data to optimize the clinical development and therapeutic potential
of new drugs
|
|
|
| |
|
Reykjavik, Iceland, February 20,
2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, February 17, 2004
|
|
|
|
Growing revenue, efficient cost structure
and strong cash position provide solid basis for advancing drug,
diagnostics pipeline
|
|
|
| |
|
Reykjavik, Iceland, February 13, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, February 11, 2004
|
|
|
|
|
|
|
| |
|
|
|
|
|
Gene encoding FLAP also confers risk for
stroke; discovery pinpoints common biological mechanism underlying
two of the world's biggest public health challenges
|
|
|
| |
|
Reykjavik, Iceland, January 23, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, January 9, 2004
|
|
|
|
|
|
|
| |
|
Reykjavik, Iceland, January 7, 2004
|
|
|
|
|
|
|
| |
